Compounded Mounjaro: What You're Actually Buying (7 Providers, Priced)

Can you actually buy "compounded Mounjaro"?

No — not literally, and not legally. Mounjaro is Eli Lilly's FDA-approved, trademarked brand name for injectable tirzepatide, approved in 2022 specifically for type 2 diabetes. A brand name belongs to the company that won FDA approval for that exact finished product: its manufacturing process, its inactive ingredients, its dose-to-dose consistency. A compounding pharmacy has no legal path to copy that finished product and sell it under Lilly's brand name. What a licensed pharmacy can do is compound tirzepatide itself, the active molecule, under its own generic name, for a specific patient with a documented reason the commercial product won't work. When an ad promises "compounded Mounjaro," it's using language for a product that doesn't legally exist — what's actually being offered is compounded tirzepatide.

This isn't a hypothetical concern. Eli Lilly has pursued the Mounjaro name specifically, more than once. In September 2023, the company sued six medical spas and wellness centers across Arizona, Florida, Georgia, Minnesota, South Carolina, and Utah for trademark infringement — alleging they marketed their own compounded tirzepatide products as "Mounjaro" itself, for weight loss, a use Mounjaro was never approved for. One of those cases, against a Charleston medical spa called Totality Medispa, ended in a May 2024 settlement requiring the spa to stop using Lilly's branding, add a disclaimer stating that compounded tirzepatide is not FDA-approved, and report any adverse events to the FDA. In April 2025, Lilly extended that fight to telehealth: it sued Mochi Health, Willow, Henry Meds, and Fella Health in federal court over marketing compounded tirzepatide as "personalized" while trading on the reputation of Lilly's approved brands. As of April 2026, a judge allowed Lilly's claims against Mochi Health to proceed under the Lanham Act and California's unfair competition law.

• Mounjaro = Eli Lilly's FDA-approved, trademarked brand name for tirzepatide, approved in 2022 for type 2 diabetes only.
• Compounded tirzepatide = the same active molecule, pharmacy-mixed under a generic name — legally, it is not Mounjaro and cannot be sold as Mounjaro.
• Eli Lilly has sued medical spas (2023) and telehealth companies (2025) specifically over marketing compounded tirzepatide using its Mounjaro and Zepbound trademarks.
• A provider that markets a product as "compounded Mounjaro" rather than "compounded tirzepatide" is using the wrong name for what it's legally allowed to sell — treat that as a signal about the provider generally, not just semantics.

Is compounded tirzepatide still legal in 2026?

Yes, but on narrower footing than during the 2022–2024 shortage years. The FDA declared the tirzepatide shortage resolved on October 2, 2024, which ended the broad exemption that had let large-scale 503B outsourcing facilities compound it without a patient-specific prescription. Those 503B facilities had until March 19, 2025 to wind that down, and courts declined to block the deadline.

What remains legal is the 503A individual-patient pathway. A state-licensed 503A pharmacy can still compound tirzepatide for a specific, named patient when a prescriber documents a genuine clinical reason the FDA-approved products — Mounjaro and Zepbound — won't work for that person, commonly an allergy to an inactive ingredient in the commercial formulation. Compounding purely because it's cheaper doesn't qualify as that clinical reason under current FDA guidance, even though cost is the reason most people are shopping this category. On top of that, on April 30, 2026, the FDA proposed removing tirzepatide entirely from the 503B bulk substances list, with a public comment period that was extended through July 30, 2026. That proposal concerns 503B bulk compounding, which has already wound down in practice — it doesn't touch the 503A rules, and no final rule has posted as of this writing.

• 503B bulk compounding of tirzepatide — ended March 19, 2025, no longer permitted.
• 503A individual-patient compounding — still legal when a prescriber documents a valid clinical reason for a specific patient.
• Cost savings alone do not qualify as a valid clinical reason under current FDA guidance.
• The FDA's April 30, 2026 proposal targets 503B bulk substances only; its comment period runs through July 30, 2026, and no final rule has been issued as of this writing.
• The FDA has sent more than 135 warning letters to GLP-1 compounders and telehealth companies since September 2025, and announced active-pharmaceutical-ingredient restrictions in February 2026, part of a broader enforcement push.

How to find a legitimate mounjaro compounding pharmacy

Searching "mounjaro compounding pharmacy near me" mostly turns up telehealth intake pages rather than a storefront you can walk into, and that's not an accident — most compounded tirzepatide today moves through a national telehealth model, not a local pharmacy counter. You complete an online intake, a licensed clinician reviews it and writes a prescription for tirzepatide, and a partnered 503A pharmacy, often based in another state, compounds and ships it to you. Some independent local compounding pharmacies will also fill a tirzepatide prescription in person if your own doctor writes one and you'd rather keep that relationship local — worth asking your PCP directly if that's your preference.

Either way, the same handful of questions separate a legitimate program from one cutting corners.

• Ask which 503A pharmacy fills the prescription — a legitimate program will name it, not just its own telehealth brand.
• Check for PCAB or state board accreditation — not a requirement, but a strong positive sign.
• Confirm a real clinical review happens — labs, history, and a documented reason for compounding, not a checkbox intake that anyone passes.
• Read exactly what's being sold — the word should be "compounded tirzepatide," not "compounded Mounjaro" or "Mounjaro alternative" used loosely.
• Verify no prescription is skipped — any site offering tirzepatide with no clinician evaluation at all is not operating legally, full stop.

Compounded tirzepatide vs. Mounjaro vs. Zepbound: what's actually different

All three contain the same active molecule, tirzepatide, manufactured or compounded to reach it. What separates them is regulatory status and labeling, not the underlying drug. Mounjaro and Zepbound went through FDA review as finished drugs — Lilly's manufacturing process, sterility controls, and dose-to-dose consistency were all evaluated before either reached a pharmacy shelf. Mounjaro carries the type 2 diabetes indication; Zepbound, approved a year later in 2023, carries the chronic weight-management indication. Compounded tirzepatide is prepared by a licensed 503A pharmacy under state pharmacy law, using tirzepatide the pharmacy sources itself, and has not gone through that same finished-product review. No independent agency has verified that a given compounded batch is sterile, correctly dosed, and consistent with the last batch — the way it has for every pen of Mounjaro and every vial of Zepbound.

Some compounded formulas also add ingredients neither brand contains, most commonly vitamin B12 or L-carnitine, marketed as supporting energy or metabolism. Those additives haven't been studied in combination with tirzepatide the way the base molecule has, regardless of how a given provider frames the benefit.

• FDA-approved indication — Mounjaro: type 2 diabetes only. Zepbound: chronic weight management. Compounded tirzepatide: no FDA-reviewed indication at all; it's not a finished, approved drug.
• Regulatory review — Mounjaro and Zepbound: FDA-reviewed as finished drugs. Compounded tirzepatide: not independently reviewed; state-licensed pharmacy compounding only.
• Format options — Mounjaro and Zepbound: injection only, pen or vial. Compounded tirzepatide: injection, and at a few providers, a dissolving oral tablet — a format neither brand offers.
• Insurance and savings cards — Mounjaro: eligible for commercial coverage and Lilly's savings card when prescribed for diabetes. Zepbound: eligible for coverage and its own savings card for weight management. Compounded tirzepatide: cash-pay only, no insurance or savings-card pathway exists.

For a fuller breakdown of the brand-name side of that comparison, see compounded Zepbound: what's actually sold, or the complete legal and provider landscape at compounded tirzepatide.

What compounded tirzepatide costs vs. Mounjaro's own price

Mounjaro's own price ladder is wider than most people expect, and it runs through a genuinely different mechanism than Zepbound's. Full retail, with no discount at all, runs about $1,020 to $1,150 a month depending on the pharmacy. Eli Lilly's savings card can bring that down sharply for commercially insured patients whose plan covers Mounjaro for diabetes: as little as $25 a month, capped at $1,950 a year. If your plan doesn't cover it, the card still knocks the price to about $499 a month. What Lilly does not offer, as of this writing, is a self-pay vial program for the Mounjaro brand itself — that program exists only under the Zepbound name, at $299 to $449 a month by dose through LillyDirect. See the full Mounjaro cost breakdown for the complete insured-tier picture.

Compounded tirzepatide sits below Mounjaro's uninsured retail price at every tier, running roughly $199 to $449 a month across the seven providers below — closer to the LillyDirect Zepbound self-pay floor than to Mounjaro's own cash price, since Mounjaro has no comparable self-pay program to compete against.

• Mounjaro, full retail, no program: roughly $12,240–$13,800/year
• Mounjaro, Lilly Savings Card (insured, covered): roughly $300/year
• Mounjaro, Lilly Savings Card (insured, not covered): roughly $5,988/year
• Compounded tirzepatide, full year: roughly $2,388 to $5,388, depending on provider and dose

The gap that matters most for most readers here isn't compounded-versus-Mounjaro's-savings-card — those two audiences barely overlap, since the $25 tier requires commercial insurance that already covers Mounjaro for diabetes. It's compounded tirzepatide versus Mounjaro's uninsured retail price, a difference that runs past $10,000 a year.

7 compounded tirzepatide providers compared

None of the seven programs below sell anything called "Mounjaro." They sell compounded tirzepatide, and how clearly each one says so, alongside its price, is part of what makes it worth your money.

Curex — lowest all-in price, correctly labeled

Curex holds the lowest verified price we can confirm, roughly $199 a month all-in, with medication, the online consult, shipping, and follow-up dose adjustments folded into one number and no separate membership fee sitting beside it. Its own site is explicit that Mounjaro and Zepbound are Lilly's proprietary brands and that Curex isn't affiliated with or supplying them — the kind of correct labeling this whole page is arguing you should look for. The caveat is the word "from": that $199 is a starter-dose rate, and the maintenance-dose price isn't publicly posted, so ask for the full ladder in writing before you enroll.

• Pros — lowest verified all-in price; no separate membership; clearly labels its product as compounded tirzepatide, not Mounjaro.
• Cons — maintenance-dose pricing isn't publicly posted; confirm before committing.

Mochi Health — flat medication price, named in Lilly's suit

Mochi prices its compounded tirzepatide medication at a flat $199 a month regardless of dose. A separate membership adds about $79 a month for care coordination and clinician access, for a real all-in cost near $278 — worth pricing as one number rather than two. Mochi is also the company whose case against Lilly a federal judge allowed to move forward in April 2026, on claims that its marketing of compounded tirzepatide as "personalized" misled patients. That's a live legal question about marketing conduct, not a finding about the medication itself, but it's worth knowing going in. Read the full Mochi Health review for the complete picture.

• Pros — flat $199 medication fee at any dose; obesity-medicine physicians; shipping included.
• Cons — separate ~$79/mo membership means the real all-in is ~$278; named in Lilly's pending 2025 lawsuit.

Eden — no membership, flat across doses

Eden sits in the honest middle of the range: no membership fee, the same rate at every dose, and a modest first-month discount. Expect roughly $249 to start and about $329 a month ongoing — a flat rate that beats some rivals' dose-scaling structures once you titrate toward the higher end. Confirm the live checkout price before you commit, since a few sources show small variation on the exact ongoing figure.

• Pros — no separate membership; flat rate across all dose tiers; the flat $329 beats dose-scaling competitors at higher doses.
• Cons — ongoing rate is higher than Curex's starter price; exact figure varies slightly by source.

Peak Wellness — watch the intro vs. ongoing rate

Peak Wellness offers flat-dose pricing with no per-tier hikes as you titrate, a real convenience. The number to watch is the timeline: the roughly $229 figure that draws attention is an intro or annual-plan rate. From the second month, or on a month-to-month plan, the price steps up to about $349. That's still a fair flat rate — it just isn't the introductory number, so budget for the standing rate rather than the teaser.

• Pros — one flat price regardless of dose; no membership fee; publicly names its compounding pharmacy.
• Cons — the ~$229 intro rate steps up to ~$349 ongoing; confirm which rate your plan locks in.

Fridays — bundled coaching, priced by commitment length

Fridays prices compounded tirzepatide as a program, not a bare prescription — coaching, a registered dietitian, and messaging support are bundled in at every tier. Expect around $389 a month with no commitment, dropping to roughly $299 a month on a longer prepay plan. If you'd otherwise be paying for coaching separately, the longer-commitment bundle reads better than the standalone medication number suggests — but the no-commitment rate is among the highest on this list.

• Pros — coaching, dietitian and app bundled; price drops meaningfully with a longer prepay commitment.
• Cons — the no-commitment monthly rate is among the highest here; best rate requires a longer prepay.

Willow — flat $399 in 33 states

Willow keeps its structure simple: a flat $399 a month at every dose, telehealth and shipping included, no separate membership. The constraint is geography — the program is currently available in 33 states, so check the list before you go through intake. If you live in a covered state and want one predictable number that won't change as you titrate, Willow delivers that. Read the full Willow review for the complete picture, including its LegitScript certification and a December 2025 NAD referral over marketing-claim substantiation.

• Pros — flat price at every dose; single all-in bill; LegitScript certified.
• Cons — available in only 33 states; higher flat rate than several rivals.

Henry Meds — oral or injectable, no membership layer

Henry Meds is one of the few programs offering compounded tirzepatide as a dissolving oral tablet alongside the standard injection, a real difference if you'd rather avoid needles. Oral runs about $349 a month and the injection about $449, with visits, supplies and shipping bundled into one price and no separate membership fee. Henry Meds is also named in Lilly's 2025 lawsuit, and the oral tablet specifically is the product the suit challenges most directly, arguing it hasn't been tested the way an oral drug normally would be. Read the full Henry Meds review before you enroll.

• Pros — oral and injectable formats; visits, supplies and shipping all bundled; no separate membership fee.
• Cons — at $349–$449 it's the highest range on this list; the oral tablet is the subject of Lilly's pending lawsuit.

Red flags when shopping for compounded tirzepatide online

Demand for cheap tirzepatide has attracted real fraud, not just aggressive marketing, so a few things are worth watching for no matter which provider you're considering.

• "Compounded Mounjaro" used as a product name, not a footnote explaining why it's different — a real misuse of a trademark, not a stylistic choice.
• Watch for "tirzepatide sodium" or "tirzepatide acetate" on a label or product page — the FDA has stated it isn't aware of a lawful basis for compounding these unapproved salt forms, and they aren't proven bioequivalent to the tirzepatide in Mounjaro or Zepbound.
• No prescription or clinician evaluation required — a hard stop regardless of price; this is a real counterfeit and dosing-error risk.
• No named pharmacy — a legitimate 503A program can tell you which licensed pharmacy fills your prescription and whether it's accredited.
• Unusual payment requests — Venmo, Zelle, cash apps, or crypto instead of standard payment processing.
• Pricing meaningfully below the ~$199 floor most legitimate 503A programs currently hold — a price that low is a sign you're not looking at a real compounded product.

Is compounded tirzepatide worth it for you — a real diabetes diagnosis, or off-label weight loss?

Mounjaro's FDA label is type 2 diabetes, and insulin resistance climbs for a lot of women through perimenopause — which means some readers landing on this page have a real, documented diagnosis, not just an off-label weight-loss interest. That distinction matters for more than the medical chart. If you have type 2 diabetes and your insurance covers Mounjaro, the $25-a-month Lilly Savings Card tier beats every compounded price on this page by a wide margin, and you'd be trading FDA-reviewed manufacturing for a lower price you don't actually need to pay. Compounded tirzepatide makes more financial sense for that group only if coverage genuinely isn't available.

If your interest is weight management rather than a diabetes diagnosis, the calculation is different. Estrogen decline through perimenopause changes where and how the body stores fat, and insulin sensitivity commonly worsens even without a formal diabetes diagnosis — both factors that make weight harder to manage through diet alone, and both reasons tirzepatide's dual GLP-1/GIP mechanism gets prescribed off-label for this group. Mounjaro isn't approved for that use, and Medicare specifically cannot cover a drug prescribed solely for weight loss. Between the three realistic paths — Zepbound's on-label, self-pay LillyDirect pricing, or a vetted compounded provider — the honest comparison is compounded tirzepatide against Zepbound, not against Mounjaro, since Mounjaro was never built for this use case in the first place.